BiotechTube

Placebo + CFZ533

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myasthenia Gravis, Generalized

Conditions

Myasthenia Gravis, Generalized

Trial Timeline

Sep 29, 2015 → Dec 19, 2017

NCT ID
NCT02565576

About Placebo + CFZ533

Placebo + CFZ533 is a phase 2 stage product being developed by Novartis for Myasthenia Gravis, Generalized. The current trial status is completed. This product is registered under clinical trial identifier NCT02565576. Target conditions include Myasthenia Gravis, Generalized.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02565576Phase 2Completed

Competing Products

20 competing products in Myasthenia Gravis, Generalized

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
77
tacrolimusAstellas PharmaPhase 3
77
Tacrolimus capsule + PlaceboAstellas PharmaPhase 3
77
tacrolimus + placeboAstellas PharmaPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
Cladribine Low Dose + Cladribine High DoseMerckPhase 3
77
Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3
77
IptacopanNovartisPhase 3
77
mycophenolate mofetil [CellCept] + PlaceboRochePhase 3
77
mycophenolate mofetil (CellCept) + placeboRochePhase 3
77
inebilizumab + IV PlaceboAmgenPhase 3
76
InebilizumabAmgenPhase 2
51
Abatacept InjectionBristol Myers SquibbPhase 1
32
Tolebrutininb + PlaceboSanofiPhase 3
76
Pozelimab + Cemdisiran + Cemdisiran + PozelimabRegeneron PharmaceuticalsPhase 3
76
HIZENTRA ®CSLPhase 2
51
Subcutaneous immunoglobulinsCSLPhase 1
32
Human normal immunoglobulin G (IgG)CSLPhase 3
76
zilucoplan (RA101495)UCBPhase 3
74
zilucoplan (RA101495) + PlaceboUCBPhase 2
49

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85